摘要
目的 :探讨骨桥蛋白(OPN)、可溶性淋巴细胞活化基因-3(sLAG-3)、Dickkop-1(DKK-1)与胃癌患者临床病理特征的关系。方法 :选取80例胃癌患者作为病例组,40例健康人员作为对照组。应用酶联免疫吸附法检测两组的OPN、sLAG-3、DKK-1水平;分析OPN、s LAG-3、DKK-1与淋巴结转移、TNM分期等临床特征的关系。结果 :病例组患者的血清OPN、sLAG-3及DKK-1水平高于对照组;血清s LAG-3水平低于对照组;低分化胃癌、TNM分期为Ⅲ~Ⅳ期及伴有淋巴结转移患者的血清OPN及DKK-1水平越高,sLAG-3水平越低(P<0.05)。经logistic逐步回归分析发现,TNMⅢ~Ⅳ期、OPN、sLAG-3及DKK-1为胃癌患者死亡的独立危险因素。结论 :OPN、sLAG-3、DKK-1与胃癌患者临床病理特征密切相关。
Objective:To investigate the relationship among osteopontin(OPN),soluble lymphocyte activation gene-3(sLAG-3),DicKKOP-1(DKK-1)and the clinicopathological characteristics of patients with gastric cancer.Methods:Eighty patients with gastric cancer were selected as a case group and 40 healthy persons were enrolled as a control group.The levels of OPN,sLAG-3 and DKK-1 in the two groups were determined by enzyme-linked immunosorbent assay.The relationship among OPN,sLAG-3,DKK-1 and the clinical characterization of lymph node metastasis and TNM stage was analyzed.Results:The serum levels of OPN,sLAG-3 and DKK-1 were higher but sLAG-3 level was lower in the case group than the control group(P<0.05).The higher the serum OPN and DKK-1 levels,the lower the sLAG-3(P<0.05).Logistic regression analysis showed that TNM III-IV stage(OR=2.171,95%CI=1.080-4.361),OPN(OR=1.528,95%CI=1.134-2.058),sLAG-3(OR=1.925,95%CI=1.108-3.346),and DKK-1(OR=2.059,95%CI=1.033-4.104)were independent risk factors for the death of gastric cancer patients.Conclusion:OPN,sLAG-3 and DKK-1 levels are closely related to the clinicopathological characteristics of the patients with gastric cancer.
作者
柳长明
崔国利
赵广阳
程开
LIU Changming;CUI Guoli;ZHAO Guangyang;CHENG Kai(Department of General Surgery,Sami Medical Center,Guangdong Shenzhen 518118,China;Department of Laboratory the First Hospital affiliated to Jiamusi University,Heilongjiang Jiamusi 154007,China;the Third Departments of Cardiovascular Medicine,the First Hospital affiliated to Jiamusi University,Heilongjiang Jiamusi 154007,China;the Second Department of Gastroenterology,the First Hospital affiliated to Jiamusi University,Heilongjiang Jiamusi 154007,China)
出处
《上海医药》
CAS
2020年第17期36-38,共3页
Shanghai Medical & Pharmaceutical Journal
基金
黑龙江省卫生厅科研课题(2010-501)。